A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

NCT07357727 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

460

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Myelofibrosis (PMF)
Post-polycythemia Vera Myelofibrosis (PPV-MF)
Post-essential Thrombocythemia Myelofibrosis (PET-MF)

Interventions

DRUG: Pelabresib
DRUG: Ruxolitinib
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals